Compare TG Therapeutics Inc (TGTX) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Ultra Short Bond ETF — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Vanguard Ultra Short Bond ETF trades at $49.69. The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| TGTX | VUSB | |
|---|---|---|
Market Cap | $7.64B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $59.06 | $50.03 |
52-Week Low | $26.94 | $49.60 |
Enterprise Value | $7.84B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
VUSB trades at $49.685, showing minimal daily movement with a 0.05% gain. Technical indicators signal a bearish trend, with moving averages and key momentum oscillators like the ADX indicating selling pressure. Recent news highlights the ETF's focus on short-term bonds amid expectations of Federal Reserve rate hikes, positioning it as a potential hedge against interest rate risk.
The outlook for VUSB is cautious due to bearish technical signals and sensitivity to interest rate changes. Opportunities lie in its short-term bond strategy if rates rise, but risks include market volatility and economic shifts. Investors should weigh the ETF's defensive role against prevailing macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
